Form 4: Vaxcyte Director Peter Hirth Reports Stock Transactions in Recent SEC Filing

Director Peter Hirth of Vaxcyte, Inc. reports acquisition of restricted stock units and stock options, along with adjustments to existing holdings, in a Form 4 filing with the SEC.

Summary

• Peter Hirth, a director of Vaxcyte, Inc., filed a Form 4 with the SEC detailing changes in his beneficial ownership of the company's stock.
• On June 6, 2024, Hirth acquired 1,550 shares of common stock underlying restricted stock units (RSUs) and 7,250 shares via stock options.
• The RSUs will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to continuous service.
• The stock options will vest monthly and fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to continuous service.
• Hirth also indirectly owns 7,113 shares through Hirth Enterprises LLC.
• The filing also includes a Power of Attorney, effective June 7, 2024, authorizing certain individuals at Vaxcyte and Skadden, Arps, Slate, Meagher & Flom LLP to act on Hirth's behalf for Section 16 filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a standard disclosure of stock transactions by a company director. The acquisition of RSUs and stock options could be seen as a slightly positive signal, but it's a routine event.

Positives

• The acquisition of RSUs and stock options could be interpreted as a sign of confidence in Vaxcyte's future prospects by a company director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• Shareholders may view the director's stock acquisitions as a positive sign of confidence in the company's future.

Key Dates